Search results for "AGENT"

showing 10 items of 8904 documents

Anesthetics and Cerebral Protection in Patients Undergoing Carotid Endarterectomy

2015

EREBRAL ISCHEMIA/HYPOXIA may occur in a vari-ety of perioperative circumstances. The main pathophy-siologic aspects involved in cerebral ischemia/reperfusion arecaused by adenosine triphosphate (ATP) consumption, theexcitotoxic actions of glutamate, changes in ionic homeostasis,and formation of free radicals (Fig 1). Outcomes from suchevents range from subclinical neurocognitive deficits to cata-strophic neurologic morbidity or death.

medicine.medical_specialtymedicine.medical_treatmentIschemiaCarotid endarterectomyAnesthesia GeneralNeuroprotectionSevofluraneBrain Ischemia03 medical and health sciences0302 clinical medicine030202 anesthesiologyInternal medicinemedicineAnimalsHumansIschemic PreconditioningSubclinical infectionEndarterectomy Carotidbusiness.industryGlutamate receptorPerioperativeHypoxia (medical)medicine.disease3. Good healthNeuroprotective AgentsAnesthesiology and Pain MedicineAnesthesiaAnesthetics InhalationCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerymedicine.drugJournal of Cardiothoracic and Vascular Anesthesia
researchProduct

One week of levofloxacin plus dexamethasone eye drops for cataract surgery: an innovative and rational therapeutic strategy

2020

Background: Cataract surgery is the most common operation performed worldwide. A fixed topical corticosteroid-antibiotic combination is usually prescribed in clinical practice for 2 or more weeks to treat post surgical inflammation and prevent infection. However, this protracted schedule may increase the incidence of corticosteroid-related adverse events and notably promote antibiotic resistance. Methods: This International, multicentre, randomized, blinded-assessor, parallel-group clinical study evaluated the non-inferiority of 1-week levofloxacin/dexamethasone eye drops, followed by 1-week dexamethasone alone, vs. 2-week gold-standard tobramycin/dexamethasone (one drop QID for all schedul…

medicine.medical_specialtymedicine.medical_treatmentLevofloxacinArticleDexamethasoneCataract03 medical and health sciences0302 clinical medicineEndophthalmitisPharmacotherapyPostoperative ComplicationsLevofloxacinInternal medicinemedicineTobramycinClinical endpointHumansEndophthalmitis Cataract Intracameral cefuroximeAdverse effectDexamethasoneEndophthalmitisbusiness.industryCataract surgeryIntracameral cefuroximemedicine.diseasenot applicableAnti-Bacterial AgentsOphthalmologyItalySpain030221 ophthalmology & optometryOphthalmic Solutionsbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Bisphosphonate treatment and dental implants: A systematic review

2015

Background To analyze articles that studied patients submitted to diphosphonates therapy and who received dental implants before, during or after bisphosphonate (BP) treatment, compared to healthy patients, analyzing the increase of failure and loss of implants or bisphosphonate related osteonecrosis of the jaw (BRONJ) incidence. Material and Methods The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement was used in this study. The clinical question in “PICO” format was: In patients under bisphosphonate therapy, do dental implants placement, compared to healthy patients, increase the failure and loss of implants or bisphosphonate related osteonecrosis of t…

medicine.medical_specialtymedicine.medical_treatmentMEDLINEDentistryReview03 medical and health sciences0302 clinical medicinestomatognathic systemmedicineHumansProspective StudiesProspective cohort studyGeneral DentistryRetrospective StudiesDental ImplantsBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)DiphosphonatesRetrospective cohort study030206 dentistryBisphosphonate:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgerystomatognathic diseasesBone Density Conservation AgentsOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryOral SurgerybusinessOsteonecrosis of the jawMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review

2018

Abstract Purpose Bisphosphonate therapy is a well-established and effective treatment for postmenopausal osteoporosis and the prevention of osteoporotic fracture. However, poor adherence to and poor persistence with bisphosphonate therapy may reduce its benefits. Previous studies have documented the poor rates of adherence and persistence among postmenopausal women with osteoporosis. The objective of this systematic literature review was to evaluate adherence, persistence, and the impact of adherence and persistence on fracture risk in postmenopausal women with diagnosed osteoporosis. Methods Articles eligible for review included observational studies of the real-world use of bisphosphonate…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosisMEDLINE02 engineering and technology030204 cardiovascular system & hematologyMedication AdherencePersistence (computer science)03 medical and health sciences020210 optoelectronics & photonics0302 clinical medicineInternal medicine0202 electrical engineering electronic engineering information engineeringmedicineHumansPharmacology (medical)Osteoporosis PostmenopausalPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryBisphosphonatemedicine.diseasePostmenopauseMenopauseObservational Studies as TopicTreatment OutcomeSystematic reviewFemaleObservational studybusinessOsteoporotic FracturesBiomedical sciencesClinical Therapeutics
researchProduct

Proposal for a preventive protocol for medication-related osteonecrosis of the jaw.

2021

Background Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some patients exposed to certain drugs (antiresorptives such as bisphosphonates or denosumab, and antiangiogenic drugs). From a review of the literature it appears that there is no uniform criterion when selecting preventive measures; these vary according to author. Likewise, the measures recommended are usually general, so that in few cases they result in specific actions to be applied depending on the different variables involved such as the type of drug used, the duration of its application, the underlying pathology, the presence or absence of risk factors, etc. The aim of this stud…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosisMEDLINEReviewsleep disturbancesolder people03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectDental implantGeneral DentistryUNESCO:CIENCIAS MÉDICASProtocol (science)dental implantOral Medicine and PathologyedentulismBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosis030206 dentistrymedicine.diseaseDenosumabSystematic reviewOtorhinolaryngologyOsteoporosisSurgeryBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

The long and winding road of non steroidal antinflammatory drugs and paracetamol in cancer pain management: A critical review

2013

The aim of this review was to assess the value of NSAIDs and paracetamol in patients with cancer pain to update a previous review performed ten years ago on this topic. The approach was analytic and based on clinical considerations, rather than on raw evidence, which often does not provide useful information in clinical practice. Both published reports from an extensive search of electronic data bases were collected from January 2001 to December 2011. A free-text search method was used including the following words and their combination: “Anti-inflammatory drugs OR paracetamol OR acetaminophen” AND/OR “cancer pain”. Any randomized-controlled trial was considered. Thirteen reports fulfitted …

medicine.medical_specialtymedicine.medical_treatmentSettore MED/41 - AnestesiologiaPainlaw.inventionPain ladderRandomized controlled triallawNeoplasmsmedicineHumansPain ManagementCancer painIntensive care medicineAcetaminophenbusiness.industryPatient-controlled analgesiaAnti-Inflammatory Agents Non-SteroidalanalgesiaHematologyAnalgesics Non-NarcoticAcetaminophenKetorolacParacetamolTreatment OutcomeOncologyOpioidAnesthesiaElectronic dataAnti-inflammatory drugCancer painbusinessCancer pain; Anti-inflammatory drugs; Paracetamol; analgesiamedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct

Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review.

2020

The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe, multiorganic, and potentially life-threatening drug-induced hypersensitivity reaction, linked to several common drugs, including antiepileptics, antibiotics, and several psychotropic drugs, including clozapine. Due to the importance of clozapine in the management of treatment-resistant schizophrenia, a systematic review and characterization of clozapine-related DRESS syndrome is long overdue.This systematic review was conducted following PRISMA guidelines. PubMed, Embase, PsychINFO, and the Cochrane Library databases were independently reviewed up to 1 November 2019 for articles reporting clozapine-relat…

medicine.medical_specialtymedicine.medical_treatmentmacromolecular substances030226 pharmacology & pharmacyDrug reaction with eosinophilia and systemic symptoms03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesMedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsAntipsychoticClozapineClozapinebusiness.industrymusculoskeletal neural and ocular physiologyGeneral Medicinemedicine.diseaseDermatologyHypersensitivity reactionnervous system030220 oncology & carcinogenesisDrug Hypersensitivity SyndromePolypharmacySchizophreniabusinessmedicine.drugAntipsychotic AgentsExpert review of clinical pharmacology
researchProduct

Intravenous propofol allows fast intubation in neonates and young infants undergoing major surgery

2019

Aim of the study: In selected surgical neonates and infants, the rapidity of induction and intubation may represent an important factor for their safety. Propofol is an anesthetic characterized by a rapid onset and fast recovery time that may reduce time of anesthetic induction and improve post-anesthetic outcome. The aim of this study was to evaluate the safety and efficacy of anesthesia induction in full-term neonates and young infants after propofol bolus administration.Methods: A retrospective case-control study including infants below 6 months of age, undergoing general anesthesia between 2011 and 2013, was carried out. Patients that received intravenous propofol bolus to induce anesth…

medicine.medical_specialtymedicine.medical_treatmentsevoflurane030204 cardiovascular system & hematologyPediatricsSevofluraneintubation03 medical and health sciences0302 clinical medicineBolus (medicine)030225 pediatricsHeart ratemedicineIntubationOriginal Researchpropofolbusiness.industrylcsh:RJ1-570lcsh:Pediatricsinduction agentneonatesPulse pressureSurgeryBlood pressurePediatrics Perinatology and Child HealthAnestheticSettore MED/20businessPropofolmedicine.drug
researchProduct